ReviewArthritis research & therapy2011
Managing pregnancy in inflammatory rheumatological diseases.
Review in Arthritis research & therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 61 citations in OpenAlex.
- Infectious comorbidities in pregnant patients with rheumatic diseases.Rheumatology international · 2026Review
- Fertility and Birth Outcomes in Rheumatoid Arthritis: A Narrative Review.Rheumatology and therapy · 2026Review
- A clinical care pathway for managing pregnancy in patients with inflammatory arthritis.Clinical rheumatology · 2026Review
- When should a neonatologist consult a rheumatologist?European journal of pediatrics · 2025Review
- Pregnancy and Inflammatory Rheumatological Diseases: A Single-Center Retrospective Cohort Study.Cureus · 2023Article
- Article
- Toxic effect window of ovarian development in female offspring mice induced by prenatal prednisone exposure with different doses and time.Journal of ovarian research · 2023Article
- Competence of medical and obstetric registrars in the management of systemic lupus erythematosus in pregnancy.Obstetric medicine · 2021Article
- Premature live birth in a woman with antisynthetase syndrome following recurrent miscarriages.BMJ case reports · 2021Review
- Immunosuppressive and Immunomodulating Therapy for Atopic Dermatitis in Pregnancy: An Appraisal of the Literature.Dermatology and therapy · 2020Review
- A multidisciplinary approach to reproductive healthcare in women with rheumatic disease.Irish journal of medical science · 2020Article
- The Complement System in the Pathophysiology of Pregnancy and in Systemic Autoimmune Rheumatic Diseases During Pregnancy.Frontiers in immunology · 2020Review
- Clinical considerations for the management of psoriasis in women.International journal of women's dermatology · 2019Review
- Immunosuppression in pregnant women with renal disease: review of the latest evidence in the biologics era.Journal of nephrology · 2018Review
- Reaching a consensus on research priorities for supporting women with autoimmune rheumatic diseases during pre-conception, pregnancy and early parenting: A Nominal Group Technique exercise with lay and professional stakeholders.Wellcome open research · 2018Article
- Article
- Placental histology and neutrophil extracellular traps in lupus and pre-eclampsia pregnancies.Lupus science & medicine · 2016Article
- Enhancing the care of women with rheumatic diseases during pregnancy: challenges and unmet needs in the Middle East.Clinical rheumatology · 2016Review
- Understanding and Managing Pregnancy in Patients with Lupus.Autoimmune diseases · 2015Review
- Pre-conceptional exposure to rituximab: comment on the article by Ojeda-Uribe et al.Clinical rheumatology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Historically, pregnancy in women with many inflammatory rheumatic diseases was not considered safe and was discouraged. Combined care allows these pregnancies to be managed optimally, with the majority of outcomes being favorable. Disease activity at the time of conception and anti-phospholipid antibodies are responsible for most complications. Disease flares, pre-eclampsia, and thrombosis are the main maternal complications, whereas fetal loss and intrauterine growth restriction are the main fetal complications. Antirheumatic drugs used during pregnancy and lactation to control disease activity are corticosteroids, hydroxychloroquine, sulphasalzine, and azathioprine. Vaginal delivery is possible in most circumstances, with cesarean section being reserved for complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.